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Abstract
Background: Prostate cancer (PC) tissue contains all-trans retinoic acid (ATRA) at a
very low level (10−9 M), at least an order of magnitude lower than in adjacent nor-
mal healthy prostate cells or benign prostate hyperplasia. When this is coupled
with deregulated expression of the intracellular lipid-binding proteins FABP5 and
CRABP2 that is frequently found in PC, this is likely to result in the preferential
delivery of ATRA to oncogenic PPARβ/δ rather than retinoic acid receptors
(RARs). There are three isotypes of RARs (RARα, RARβ, and RARγ) and recent
studies have revealed discrete physiological roles. For example, RARα and RARγ
promote differentiation and self-renewal, respectively, which are critical for
proper hematopoiesis.
Aims: We have previously shown that ATRA stimulates transactivation of RARγ at
sub-nanomolar concentrations (EC50 0.24 nM), whereas an 80-fold higher concentra-
tion was required for RARα-mediated transactivation (EC50 19.3 nM). Additionally,
we have shown that RAR pan-antagonists inhibit the growth of PC cells
(at 16-34 nM). These findings, together with the low level of ATRA in PC, led us to
hypothesize that RARγ plays a role in PC pathogenesis and that RARγ-selective
antagonism may be an effective treatment.
Methods and results: We found that concentrations of 10−9 M and below of ATRA
promoted survival/proliferation and opposed adipogenic differentiation of human PC
cell lines by a mechanism that involves RARγ. We also found that a RARγ-selective
antagonist (AGN205728) potently induced mitochondria-dependent, but caspase-
independent, cell death in PC cell lines. Furthermore, AGN205728 demonstrated
synergism in killing PC cells in combination with cytotoxic chemotherapeutic agents.
Conclusion: We suggest that the use of RARγ-selective antagonists may be effective
in PC (and potentially other cancers), either as a single agent or in combination with
cytotoxic chemotherapy.
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1 | INTRODUCTION
Prostate cancer (PC) is one of the most commonly diagnosed non-
cutaneous malignancies in elderly males living in the industrialized
countries of Western Europe and North America and current esti-
mates suggest that approximately 1 in 10 men over the age 65 years
will go on to develop an aggressive metastatic form of the disease.1
Thus due to an increasingly aging population, the incidence of PC is
predicted to greatly increase over the next 30 years.2 Currently,
chemo- or radiotherapy, often coupled with androgen deprivation
therapy (ADT), is the gold-standard treatment for most PC patients.3,4
However, a highly aggressive metastatic hormone-independent form
of the disease (castration or hormone resistant prostate cancer
(CRPC) develops in a significant number of patients and the treatment
options for these patients remain limited. Even with the recent intro-
duction of improved therapeutics, the average survival time of CRPC
patients is still often less than 36 months,3,4 necessitating the devel-
opment of new and better treatment approaches.
All-trans retinoic acid (ATRA) plays crucial roles in early development,
organogenesis and tissue homeostasis by regulating the balance between
cell proliferation, differentiation and apoptosis5. ATRA serves as an acti-
vating ligand for a host of obligate dimers between one of the retinoic
acid receptor (RARα, RARβ, RARγ), and one of the retinoid X receptor
(RXRα, RXRβ, RXRγ) family members. In the absence of ligand, gene
expression is repressed, whereas ATRA binding leads to coregulator
exchange and gene activation.6 Individual RAR isotypes have different
patterns of temporal and spatial expression during prostate development,
suggesting that they play discrete roles during prostate development.7
ATRA plays a role in the development of early prostate precursor cells
derived from the murine fetal urogenital sinus,8 with signaling by RARα
or RARγ-implicated in the promotion of differentiation vs survival/prolif-
eration, respectively.9 In adults, an adequate supply of ATRA, possibly
acting via RARγ, is required for the proliferation and survival of prostate
stem cells,9 as well as the maintenance of proper prostate functional-
ity.7,8,10,11 Moreover, both ATRA-deprivation and genetic ablation of
RARγ expression block development of the murine prostate, providing
further evidence of an important role for RARγ.10 PC tissue has been
observed to contain ATRA at very low levels (in the region of 10−9 M),
which is at least an order of magnitude lower than in adjacent normal
healthy prostate cells or benign prostate hyperplasia.12 Any effects aris-
ing from low concentrations of ATRA are predicted to be compounded
by over- and under-expression, respectively, of the intracellular lipid-
binding proteins FABP5 and CRABP2, which occurs frequently in PC
13-15. In addition to functioning as a pan-RAR agonist, ATRA also acti-
vates the “orphan” nuclear receptor PPARβ/δ, which promotes prolifera-
tion and survival. Whether ATRA is diverted to RARs or oncogenic
PPARβ/δ is dependent on the FABP5:CRABP2 ratio, with FABP5 deliver-
ing ATRA to PPARβ/δ and CRABP2 delivering ATRA to RARs. It is there-
fore likely that this is likely to divert available ATRA to oncogenic
PPARβ/δ at the expense of retinoic acid receptors (RARs). It is therefore
predicted that PC cells become adapted to survive and proliferate in a
low-concentration ATRA environment, with ATRA diverted to oncogenic
PPARβ/δ at the expense of retinoic acid receptors (RARs).
Pharmacological concentrations (10−6 M) of ATRA have demon-
strated clinical efficacy in a sub-type of acute myeloid leukemia (AML)
referred to as acute promyelocytic leukemia (APL), that is generally
associated with the t(15;17)(q24;q21) reciprocal translocation
between the PML and RARA genes.16 This is primarily due to the fact
that APL is associated with few cytogenetic defects apart from t
(15;17) and the success of ATRA (in combination with arsenic trioxide)
in this case is due to its direct targeting of the PML-RARα fusion
oncoprotein.16,17 This idea is supported by the failure of ATRA to
yield positive clinical outcomes in other cancers.18-21 This may also be
due, at least in part, to the fact that ATRA elicits pleiotropic effects—
most likely as a result of multiple RAR isotype-specific actions.22,23
Thus, ATRA may be of limited therapeutic usefulness in complex
tumors and approaches that do not incorporate pan-agonism of RARs,
ideally utilizing isotype-specific agonists and/or antagonists may
prove useful. Consistent with this notion, we have previously shown
that, in contrast to ATRA, pan-RAR antagonists induced growth arrest
and apoptosis in PC cell lines and primary patient samples, while nor-
mal prostate epithelial cells displayed reduced sensitivity.24,25 In this
study, we therefore sought to investigate how ATRA concentration
affects the growth and survival characteristics of PC cell lines and




The synthetic retinoids AGN195183, AGN205327, AGN194310,
AGN196996, and AGN205728 (Figure 1 and Table 1) were synthe-
sized at the Shanghai Institute of Materia Medica. Their synthesis,
development, and specificities have been described previously in
Hughes et al and references within.26 All-trans-retinoic acid (Cat. #
0695); the pan-RAR agonist TTNPB (4-[(E)-2-(5,6,7,8-Tetrahydro-
5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, Cat. #
0761)27; the RARα-selective agonist AM580 (4-[(5,6,7,8-Tetrahydro-
5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid, Cat. #
0760)28; the PPARγ-selective agonist ciglitazone (Cat. # 1307)29; the
PPARγ-selective irreversible antagonist GW9662 (Cat. # 1508)30; the
microtubule stabilizer docetaxel (Cat. # 4056); the thymidylate syn-
thetase inhibitor 5-fluorouracil (Cat. # 3257); and the topoisomerase II
inhibitor etoposide (Cat. # 1226) were purchased from Tocris Biosci-
ences. Retinoids were dissolved in 50% methanol/50%
dimethylsulphoxide (DMSO) at a concentration of 10 mM (stored at
−20C), and this stock was diluted using culture medium to the
required concentration.
2.2 | Cell lines and cell culture
RWPE-1 (ATCC# CRL-11609, RRID:CVCL_3791); LNCaP (ATCC#
CRL-1740, RRID:CVCL_1379); DU 145 (ATCC HTB-81, RRID:
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CVCL_0105) and PC-3 (ATCC# CRL-1435, RRID:CVCL_0035) cells
were purchased specifically for this study from the American Type
Culture Collection (ATCC, Manassas, VA). The LNCaP,31 DU 14532
and PC-333 cell lines were derived from metastatic prostate carci-
noma. The poorly invasive, androgen-dependent LNCaP cell line
expresses RARA and RARG mRNA, and RARα and RARγ, but not RARβ
protein.34,35 There are conflicting data regarding expression of RARB
mRNA in LNCaP cells.34-37 DU145 and PC3 cells exhibit androgen-
independent growth and express RARA and RARG, but RARG mRNA,
and also RARα and RARγ, but not RARβ.34,35 Human prostate epithe-
lial non-neoplastic RWPE-1 cells38 express RARα and RARγ, but not
RARβ.37 Cell cultures were maintained under serum-free conditions
using the Prostate Epithelial Cell Growth Medium (PrEGM) BulletKit
(Cat. # CC-3166, Lonza) minus retinoic acid in the presence of antibi-
otics (Lonza). For experiments, cells were seeded in RPMI-1640 sup-
plemented with ×1 ITS+1 liquid media (containing insulin, transferrin,
selenium dioxide, linoleic acid, and bovine serum albumin, Merck) in
the presence of antibiotics (100 U mL−1 penicillin and 100 μg mL−1
streptomycin Lonza).
2.3 | Analysis of cell growth
Cell proliferation was determined either by direct cell count or indi-
rectly using the ViaLight Plus Cell Proliferation and Cytotoxicity Bio-






F IGURE 1 Structures of ATRA and retinoid analogs used in this study. Transactivation properties are detailed in Table 1
TABLE 1 Binding affinities of
synthetic retinoids at different retinoic
acid receptor isoforms
ED50 (nM)
Retinoids RARα RARβ RARγ Classification
Retinoic acid receptor agonists
AGN195183a 20.1 >5000 >5000 RARα-selective agonist
AGN205327b 3766.0 734 32 RARγ-selective agonist
Retinoic acid receptor antagonists
AGN194310c 4.3 5 2 RARαβγ antagonist
AGN196996d 3.9 4036 >10 000 RARα-selective antagonist
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described.25 Briefly, cells were seeded (400 cells per well) in RPMI-
1640 + ITS+1 culture medium in 96-well microtitre plates and treated
with retinoids both immediately and at day 2 by replacing the
medium. The number of viable cells was assessed at day 5 by measur-
ing cellular ATP levels.
2.4 | Analysis of colony forming potential
Single cell suspensions of serum-free adapted PC cells were prepared
by trypsinization of 80% confluent plates using 0.25% (v/v) trypsin in
phosphate-buffered saline for 5 minutes at 37C. Single cell suspen-
sions containing <90% viable cells as measured by trypan blue exclu-
sion were discarded. Cells were seeded at a density of 1000 cells per
65-mm diameter plastic cell culture dish. Cells were incubated for
21 days at 37C in 5% CO2 in 4 mL of RPMI 1640 plus ITS
+1. Culture
medium was replaced every 5 days, and after 21 days cells were fixed
using 1% (v/v) formaldehyde in 0.9% (v/v) NaCl and stained with 1%
(v/v) methylene blue in 0.9% (v/v) NaCl. Colony-forming efficiency
was determined by counting the number of colonies that formed:
(number of colonies formed/number of cells inoculated) × 100. Deter-
mination of clone morphology (holoclone, meroclone, or paraclone)
was performed as previously described.39
2.5 | Analysis of transactivation
Transactivation assays using CV-1 kidney fibroblast cells have been
described previously.40 Briefly, CV-1 kidney fibroblast cells were first
transiently transfected with a mammalian plasmid vector (ERE-Tk-
Luc)41 that expresses Firefly luciferase under the transcriptional regu-
lation of the Xenopus vitellogenin estrogen response element (ERE),
together with the pGL4.70[hRluc] Renilla luciferase control vector
(Promega). Cells were also co-transfected with expression vectors
encoding a fusion protein comprising the estrogen receptor DNA-
binding domain and the ligand-binding domains of either RARα, RARβ,
or RARγ. Cells were transfected using Lipofectamine (Thermo)
according to the manufacturer's instructions. Twenty-four hours post-
transfection, cells were treated with increasing concentrations of
ATRA (10-10-10-6) for 16 hours in culture medium-containing 2.5%
charcoal-stripped FBS (Merck). Transactivation was measured using
the Dual-Luciferase Reporter Assay System (Promega). Firefly lucifer-
ase reporter activity was normalized against Renilla luciferase activity,
and transactivation data are presented as the percentage of the maxi-
mal response produced by 1 μM ATRA.
2.6 | Analysis of adipogenic differentiation
Adipocyte differentiation was induced in serum-free adapted LNCaP,
PC-3 or DU145 as described by Zhau et al.42 Briefly, cells were plated
at a density of 3 × 105 cells/dish in 60 mm cell culture dishes in RPMI
1640 plus ITS+1. In order to induce adipogenic differentiation, this
growth medium was supplemented with dexamethasone (10−7 M),
indomethacin (5 × 10−5 M), and the phosphodiesterase inhibitor
3-isobutyl-L-methyl-xanthine (IBMX, 5 × 10−5 M). Adipogenic differ-
entiation medium was refreshed every 3 days and adipogenesis was
assessed by Oil red O staining on day 14 and day 21. Cells were
washed with ice cold PBS and fixed in 5% formaldehyde (v/v in PBS)
for 1 hour. Cells were washed and incubated for 15 minutes with
1 mL of Oil red O (0.6% [w/v] in 60% isopropanol/ PBS 1:1 v/v). After
washing, cell-bound Oil red O was extracted in 1 mL isopropanol and
absorbance was measured at 510 nm. Values were normalized using
the ViaLight Plus Cell Proliferation and Cytotoxicity BioAssay Kit
(Lonza).
2.7 | Antibody transfection
Serum-free grown LNCaP cells were transfected with antibodies
directed against either RARα or RARγ (Chariot, Active Motif)43
according to the manufacturer's recommendations. In brief, 50 μg of
antibody and 1 μg of β-galactosidase were resuspended in 100 μL ×2
sterile phosphate-buffered saline (PBS) and mixed with freshly soni-
cated Chariot transfection reagent (6 μL of reagent re-constituted in
100 μL sterile H2O). This mixture was incubated at room temperature
for 30 minutes to form the transfection complex reagent. LNCaP cells
(5 × 105) were washed twice with pre-warmed serum-free RPMI
1640 and the final cell pellet was mixed with the antibody/Chariot
mixture and incubated at 37C in a humidified atmosphere containing
5% CO2. After 30 minutes a further 400 μL of serum-free RPMI 1640
were added to the cells to achieve the final transfection concentra-
tion. The LNCaP cells were incubated at 37C for a further 5 hours to
allow internalization of the antibody. Control cells were treated with
the Chariot reagent alone (6 μg in 200 μL of sterile PBS). After anti-
body transfection, the cells were washed twice in RPMI 1640 + ITS+1
and re-suspended in a volume of 1 mL. A 100-μL aliquot of cells was
removed, fixed and stained for β-galactosidase expression to assess
transfection efficiency. Cells were grown for a further 12 days at
which time colonies were fixed with 2% buffered formaldehyde,
washed and stained with 1.25% (w/v) crystal violet stain. Polyclonal
antiserum to RARα was a generous gift from Dr P. Chambon (Institute
for Genetics and Cellular and Molecular Biology, Strasbourg, France),
and the antibody to RARγ (Cat. # sc-550) was purchased from Santa
Cruz Biotechnology Inc.
2.8 | Cell cycle analysis
Cell cycle status was measured by staining harvested cells with
propidium iodide (PI, Molecular Probes) according to the manufac-
turer's instructions. The distribution of cells between phases of the
cell cycle was determined using a FACS Calibur flow cytometer and
the CellFIT cell-cycle analysis software (Becton-Dickinson). The cell
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cycle distribution is shown as the percentage of cells containing 2n
(G1 phase), 4n (G2 and M phases) and 4n > 3 > 2n DNA amount
(S phase) judged by propidium iodide staining. The apoptotic popula-
tion is defined by the percentage of cells with DNA content lower
than 2n (sub-G1 phase).
2.9 | Analysis of apoptosis
Apoptosis-associated DNA fragmentation was measured using the
TACS 2 TdT Fluorescein in situ apoptosis detection kit (Trevigen).
Briefly, serum-free adapted PC cells were seeded at a density of
5 × 105 cells per 75 cm2 flask and treated with retinoids of vehicle
control. Treated cells (both adherent cells and those in suspen-
sion) were trypsinized, cytospun onto microscope slides and ana-
lyzed according to the manufacturer's instructions. Induction of
apoptosis was assessed using fluorescence microscopy and quan-
tified by counting five separate fields of view (minimum of
500 cells).
Activation of caspase was measured essentially as described by
Keedwell et al.25 The pan-caspase inhibitor Z-VAD-FMK (R&D Sys-
tems) was used to investigate the involvement of caspases in
AGN205728-induced apoptosis. A 20 mM stock solution was pre-
pared in DMSO. Z-VAD-FMK was added at 50 μM to bulk cultures of
cells 1 hour before adding AGN205728, and cells were monitored
using the TUNEL assay. Fluorometric assays for caspase activity were
conducted in 96-well microtiter plates. In total, 50 μL of assay buffer
(20 mM HEPES, pH 7.5, 10% glycerol, 2 mM dithiothreitol) containing
50 μM of peptide substrates for caspase-3 (DEVD-AFC), caspase-8
(IETD-AFC), or caspase-9 (LEHD-AFC) (all from Biovision Inc.) were
added to each well. In total, 50 μL of cell lysate were added to initiate
the reactions. Backgrounds were measured in wells that contained
assay buffer, substrate, and lysis buffer. Fluorescence was measured
on a CytoFluor 4000 fluorescence plate reader (Applied Biosystems)
set at 400 nm excitation and 508 nm emission. Caspase activities
were calculated as fold increases relative to control wells.
2.10 | Software, data manipulation and statistical
analyses
At least three experiments of each type were performed with tripli-
cate replicates. Results are expressed as means ± SD (± SD). Statistical
significance between groups of data was analyzed by unpaired t-test
or 2-way ANOVA as appropriate using GraphPad Prism (GraphPad
Software, La Jolla, CA) or SigmaStat (Systat Software, San Jose, CA).
Statistical significance is represented as follows: ns (not significant),
P ≥ .05; *, P < .05; **, P < .01; ***, P < .001; ****, P ≤ .0001. Dose-
response curves for compounds were plotted using the kinetics mod-
ule of SigmaPlot (Systat Software, San Jose, CA). Marvin was used for
drawing and displaying chemical structures of ATRA and synthetic ret-
inoids (Marvin 19.12, 2019, ChemAxon).
3 | RESULTS
3.1.1. | Low concentrations of all-trans retinoic acid
stimulate proliferation and colony forming ability of
prostate cancer cells
In light of our hypothesis that PC cells may be adapted to survive
and proliferate in a low ATRA concentration environment, we ini-
tially sought to titrate ATRA against three model PC cell lines
derived from metastatic prostate carcinoma: LNCaP, PC-3, and
DU145. We found that in all three PC cell lines, ATRA treatment
for 5 days within the range of 10−11-10−9 M resulted in an
increase in cell numbers of up to 1.5-fold (Figure 2A). By contrast,
treatment ATRA at concentrations of 10−8 M and above progres-
sively diminished cell growth. In order to assess the long-term
effects of low vs high concentrations of ATRA on cell growth and
survival, we performed single-cell clonogenic assays on LNCaP,
PC-3 and DU145 cells and RWPE-1 cells, which are derived from
HPV-18-transformed epithelial cells from the peripheral zone of
normal prostate. Consistent with our 5-day ATRA treatment
results, we found that for all three PC cell lines treatment with
10−10 M ATRA increased the colony forming efficiency (CFE)
while treatment with 10−6 M ATRA decreased CFE (Figure 2B). By
contrast, non-tumorigenic RWPE-1 cells, which untreated had a
low CFE of 0.43, failed to respond to either high or low concentra-
tions of ATRA. These results indicated that treatment of malignant
PC cell lines with low nanomolar concentrations of ATRA favors
survival/proliferation of the clonogenic fraction, whereas higher
pharmacological concentrations promote growth arrest and/or
differentiation.
When subjected to single cell clonogenic assays, malignant PC
cells produce colonies of three different types: holocolone (comprising
large cells with homogeneous morphology), meroclone (comprising
cells with intermediate size and heterogeneous morphology), and par-
aclone (comprising smaller cells with homogeneous morphology).
These morphologically distinct types of colonies are considered to
contain cells that possess stem cell-like (holocolone), early progenitor
(meroclone), or late progenitor/differentiation-committed (paraclone)
characteristics. In the absence of ATRA, around 70% of colonies
formed by serum-free adapted LNCaP displayed typical39 large
holoclone/meroclone morphologies with the remaining 30% con-
taining cells with the smaller, differentiated paraclone morphology
(Figure 2C). Treatment with 10−10 M ATRA increased the proportion
of colonies displaying morphologies consistent with stem cell-like or
early progenitor status to around 85%. Treatment with 10−6 M ATRA,
on the other hand, increased the proportion of colonies displaying late
progenitor/differentiation-committed (paraclone) characteristics to
more than 60%. Taken together, these results suggested that the low
physiological concentrations of ATRA found in PC serve to either
increase the clonogenic (stem cell) population by providing a stem-cell
specific survival stimulus or block entry of this cell population into a
spontaneous differentiation/apoptosis programme.
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3.1.2. | Agonism of RARγ promotes growth and
inhibits adipogenic differentiation in prostate
cancer cells
ATRA is the natural endogenous ligand for all three RAR isotypes and
they display similar binding affinities for this retinoid (RARα,
0.37 × 10−9 M; RARβ, 0.37 × 10−9 M; RARγ, 0.22 × 10−9 M).44
However, we and others have previously shown that while ATRA
stimulates transactivation in CV-1 cells via RARβ and RARγ at sub-
nanomolar concentrations, much higher concentrations are required
for RARα-mediated transactivation.44,45 We also observed this phe-
nomenon in LNCaP prostate cancer cells (that do not express RARβ),
where RARγ displayed a half-maximal response (EC50) value of
0.24 × 10−9 M while RARα displayed an EC50 value of 19 × 10−9 M,
which was 79-fold higher. This prompted us to investigate whether
individual RAR isotypes played a role in the differential response of
PC cells to low vs high concentrations of ATRA. Consistent with our
prior data, we found that RARβ and RARγ displayed EC50 values of
0.39 × 10−9 M and 0.36 × 10−9 M, respectively, while ATRA had a
minimal effect on transactivation via RARα at concentrations below
10−9 M (EC50 = 12.4 × 10
−9 M) (Figure 3A-C). This represented a
30-fold difference and maximal transactivation by RARα did not occur
until 10−6 M. We then examined the growth response of LNCaP cells
of RAR isotype-selective agonists in comparison to the pan-RAR ago-
nist ATRA (Figure 3D). In line with results suggesting opposing roles
for RARα and RARγ in prostate growth and differentiation (and poten-
tially in PC), the RARγ-selective agonist AGN205327 elicited an effect
on LNCaP cells that mirrored ATRA while the RARα-selective agonists
AM580 and AGN195183 failed to promote cell growth at low con-
centrations. It is also important to note that the modest inhibition in
the growth of LNCaP cells and concentrations greater than 10−6 M
can be explained by a loss of receptor specificity and subsequent
agonism of RARα at high concentrations (Table 1). Further supporting
the notion that, in contrast to RARγ, RARα has anti-growth and pro-
differentiative role PC, co-treatment of AGN195183 with an RARα-
selective antagonist (AGN196996) abolished AGN195183-mediated
growth inhibition in LNCaP cells (Figure 3E). Moreover, co-treatment
of ATRA with AGN196996 promoted proliferation of LNCaP cells,
likely due to activity of ATRA on RARγ.
PC cell lines contain a sub-population of cells that possess charac-
teristics similar to mesenchymal stem cells that, upon appropriate
stimulation, can undergo neuroendocrine, adipogenic, or osteoblastic
differentiation.42 When grown in a pro-differentiative culture medium
containing dexamethasone, indomethacin, and the phosphodiesterase
F IGURE 2 Low doses of all-
trans retinoic acid stimulate
growth of prostate cancer cell
lines. (A) Serum-free adapted
LNCaP, PC-3 and DU145 cells
were treated with ATRA at the
indicated concentrations. Results
are presented as the mean
number of cells recovered (±SD).
(B) The ability of serum-free
adapted LNCaP, PC-3, or DU145
cells to form colonies in response
to 10−10 M and 10−6 M ATRA as
indicated was analyzed by
methylene blue staining. Results
are presented as mean colony-
forming efficiencies (±SD).
(C) Serum-free adapted LNCaP
cells were treated with 10−10 M
and 10−6 M ATRA as indicated
and assessed for ability to form
holoclone/meroclone, or
paraclone colonies. Results are
presented as the percentage of
colony types as indicated.
Statistical significance is
represented as described in
Section 2
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inhibitor IBMX, lipid droplets began to form within cells and
10-12 days post-induction of differentiation, lipid accumulation may
be quantitatively analyzed. In agreement with our results suggesting
that, via either RARα or RARγ, ATRA can elicit either pro- or anti-
growth and differentiation responses in PC, it has also been reported
that ATRA can block the differentiation of pre-adipocyte-like cells into
lipid-loaded adipocytes in several model systems.46-50 We therefore
examined whether RARγ agonism could inhibit adipogenic differentia-
tion in PC cell lines. Oil red O staining showed that treatment with
AGN205327 (10−7 M) was able to inhibit the accumulation of lipid
droplets by around 50% (Figure 3F). These results were of a similar
order to those obtained with the PPARγ antagonist GW9662
(10−5 M). We also examined the ability of AGN205327 to diminish
adipogenic differentiation arising from PPARγ agonism (Figure 3G).
We found that induction of adipogenic differentiation in LNCaP cells
by the PPARγ agonist ciglitazone (10−7 M) was inhibited by up 70%
when AGN205327 (10−7 M) was given at time points ranging
between 48 hours pre- and post-addition of ciglitazone. Addition of
F IGURE 3 Legend on next page.
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AGN205327 later than 48 hours post-induction of adipogenesis failed
to have any effect on ciglitazone-induced adipogenesis, which is con-
sistent with studies showing that retinoids can only block
adipogenesis when added during the early commitment phase.47,50,51
3.1.3. | Antagonism of RARγ inhibits growth and
colony formation in prostate cancer cells
Our results showing that RARγ agonism could promote growth and
clonogenicity, and inhibit differentiation strongly suggested that
RARγ-selective antagonism could have the opposite effects. This is in
line with our previous data showing that treatment of LNCaP cells
with pan-RAR antagonist AGN194310 (Figure 1, S1A, S1D and
Table 1) inhibited colony formation.25 Consistent with these observa-
tions, the RARγ-selective antagonist AGN205728 (Figure 1, S1B, S1E
and Table 1) diminished the CFE of all three PC cell lines in a fashion
similar to AGN194310 (Figure 4A). Treatment with neither ATRA, nor
the RARα-selective antagonist AGN196996 (Figure 1, S1C, S1F and
Table 1) proved as effective AGN205728 or AGN194310. These data
indicate that antagonism of RARγ alone is sufficient to reduce colony
formation in PC cell lines. The growth inhibitory effect of treatment
AGN205728 in PC cell lines was observed also in short-term assays,
with concentrations of 10−6 M and above abolishing metabolic activ-
ity (Figure 4B). By contrast, non-tumorigenic RWPE-1 cells showed
significantly diminished response to AGN205728. Consistent with
this, AGN194310 and AGN205728 but not AGN196996 were able to
diminish RAR-mediated transactivation stimulated by ATRA
(Figure 4C).
While the EC50 data indicated a high degree of selectivity
AGN205728 towards RARγ (Table 1), strongly supporting a role for
this RAR isotype in the pathology of PC, we nevertheless wanted to
demonstrate the role of RARγ by other means. To this end, we took a
completely different approach to abrogating activation of RARγ and
used an anti-RAR antibody to interfere with its function (Figure 4D).
Transfection with this “neutralizing” antibody phenocopied treatment
with AGN205728 and diminished CFE, both with and without low
dose (10−11 M) ATRA. This result validated RARγ as a bona fide thera-
peutic target, at least as far as in vitro studies permit. By contrast, and
consistent with results from RARα-selective antagonism, treatment
with a neutralizing antibody raised against RARα failed to block
increases in CFE arising from low dose ATRA treatment. These data
reveal that antagonism of RARγ is sufficient to inhibit the growth PC
cell lines in vitro and non-malignant prostate cells display reduced
sensitivity to this treatment.
3.1.4. | Antagonism of RARγ in LNCaP cells induces
growth arrest followed by caspase-independent
apoptosis
In order to understand the mechanisms underlying the inhibition of
growth and clonogenic potential we observed upon abrogation of
proper RARγ function, we first analyzed the effects of treatment with
AGN194310 (10−6 M) or AGN205728 (10−6 M) on the cell cycle
(Figure 5A). The proportion of cells in G1 phase of the cell cycle grad-
ually increased following treatment with AGN194310 or
AGN205728, which was paralleled by a fall in the proportion of cells
found in S-phase. After 12 hours the proportion of cells identified as
sub-G0/G1 (indicative of apoptosis) started to rise until at the
48-hour timepoint almost 60% of cells were sub-G0/G1 following
AGN194310 treatment and almost 40% of cells were sub-G0/G1 fol-
lowing AGN205728 treatment. The accumulation propidium iodide-
stained DNA in sub-G0/G1 compartment indicated that cellular DNA
had begun to fragment, a biomarker of apoptotic or necrotic cell
death. Time-course agarose gel electrophoresis analysis of DNA from
AGN205728-treated LNCaP cells revealed a discrete laddering pat-
tern that is typical of cells undergoing apoptosis rather the more gen-
eralized smeared pattern that is associated with necrosis (Figure 5B).
A quantitative readout of the percentage of cells undergoing apopto-
sis following treatment with AGN194310 (10−6 M) or AGN205728
(10−6 M) was obtained using the terminal deoxynucleotide transferase
F IGURE 3 RARγ promotes growth and inhibits differentiation of prostate cancer cell lines. (A-C) CV-1 cells were transiently transfected with
expression vectors encoding a fusion protein containing the estrogen receptor (ER) DNA binding domain (DBD) and the ligand binding domain
(LBD) of the indicated RAR isotype, together with a firefly luciferase reporter under the control of an estrogen response element (ERE-Tk-Luc).
Differences in transfection efficiency between samples were normalized using a control vector constitutively expressing Renilla luciferase.
Transfected cells were treated with (A) ATRA, (B) AGN195183, or (C) AGN205327 at the indicated concentrations for 24 hours analyzed for
luciferase activity. Results shown are from a typical experiment performed in triplicate and are expressed as relative light units (RLU, arbitrary
units) ± SD that have been normalized to the maximal response to ATRA (10−6 M). The compound concentrations at which half-maximal effect is
observed (EC50) for RARα, RARβ, or RARγ are indicated. (D) Serum-free adapted LNCaP cells were treated with the indicated concentrations of
pan-RAR agonist ATRA, RARγ-selective agonist AGN205327, RARα-selective agonists AGN195183 and AM580. Results are presented as the
mean number of cells recovered (±SD). (E) Serum-free adapted LNCaP cells were treated for 4 days with ATRA (10−8 M), AGN195183 (10−8 M)
and the RARα-selective antagonist AGN196996 (10−8 M) as indicated. Results are presented as the mean number of cells recovered (±SD).
(F) Serum-free adapted LNCaP, PC-3, or DU145 cells were grown in differentiation medium without compound (Control), containing AGN205327
(10−7 M) or PPARγ-selective antagonist GW9662 (10−5 M) as indicated. 14 days post-induction of differentiation, cells were tested for lipid
droplet accumulation using the Oil red O assay. Results are presented as mean fold increase in absorbance at 510 nm (±SD) relative to
undifferentiated serum-free adapted cells (Untreated). (G) Adipogenic differentiation of serum-free adapted LNCaP cells was induced by
treatment with PPARγ-selective agonist ciglitazone (10−6 M). AGN205327 (10−7 M) was added at the indicted times pre- or post-treatment with
ciglitazone. Cells were analyzed and results presented as described in (F). Statistical significance is represented as described in Section 2
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end-labeling (TUNEL) assay (Figure 5C). After 24 hours, the percent-
age of cells undergoing apoptosis gradually increased until 60 hours
post-treatment the proportion of apoptotic cells reached 35% and
40% for AGN194310 and AGN205728, respectively. Again, among
the untreated cells and the AGN196996-treated sample there was lit-
tle evidence of induction of apoptosis. We then assessed the contri-
bution of caspases to AGN205728-associated induction of apoptosis.
Here, we found that pre-treatment with the pan-caspase inhibitor
Z-VAD-FMK (5 × 10−5 M) failed to diminish induction of apoptosis by
AGN205728 (Figure 5D) and, furthermore, AGN205728 failed to acti-
vate caspases-3, −8 or −9 (Figure 5E).
Chemotherapy has been one of the mainstays in the treatment of
castration-resistant PC, including the taxanes, carbazitaxel, and doce-
taxel.52 These agents induce caspase-dependent apoptosis (similar to
RARα agonism) in numerous PC cell lines, which prompted us to test
docetaxel in combination with low-dose AGN205728 (10−7 M). We
found that the combination of AGN205728 and docetaxel led to a
significant reduction in cell viability compared to their use as single
agents (Figure 5F). Similar results were obtained with the pyrimidine
analog 5-fluorouracil (5-FU) and the topoisomerase 2 inhibitor
etoposide.
4 | DISCUSSION
Retinoic acid signaling in prostate carcinoma cells is complex and our
data strongly suggest that is at least in part because RARα and RARγ
play opposing roles in the promotion of differentiation and prolifera-
tion/survival, respectively. This notion is in agreement with studies in
breast carcinoma cell lines showing that RAR isoforms have opposing
and, perhaps, mutually antagonistic roles in controlling prolifera-
tion.14,53-56 While RARγ supports the proliferation and survival of
malignant breast epithelial cells RARα, on the other hand, inhibits pro-
liferation and promotes differentiation. Our results suggest that this
F IGURE 4 Antagonism of RARγ inhibits growth of prostate cancer cell lines. (A) The ability of serum-free adapted LNCaP, PC-3, or DU145
cells to form colonies was analyzed in response to treatment with ATRA, AGN196996, pan-RAR antagonist AGN194310, or RARγ-selective
antagonist AGN205728 at the indicated concentrations. Results are presented as mean colony-forming efficiencies (±SD). (B) Serum-free adapted
LNCaP, PC-3, DU145, or RWPE-1 cells were treated with AGN205728 as indicated. Metabolic activity (intracellular ATP concentration) was
measured using the Vialight HS High Sensitivity Cell Proliferation/Cytotoxicity assay. Results are presented as percentage of viable cells relative
to control (±SD). (C) Serum-free grown LNCaP cells were treated 5 × 10−8 M AGN196996, AGN194310, or AGN205728 or vehicle control as
indicated for 12 hours prior to stimulation with 10−10 M ATRA. After 96 hours cells, cells were harvested by trypsinization and counted. The data
are presented as the mean number of cells recovered from three separate flasks (±SD). (D) Serum-free grown LNCaP cells were transfected with
polyclonal antibodies directed against RARα or RARγ as indicated. Cells were grown for 12 days post-transfection ± ATRA as indicated and
analyzed for ability to form colonies. Results are presented as mean colony-forming efficiencies (±SD). Statistical significance is represented as
described in Section 2
PETRIE ET AL. 9 of 13
complexity is due, at least in part, to concentration-dependent differ-
ential responses of RAR isotypes to ATRA. At low nanomolar levels,
RARγ is activated preferentially, while higher concentrations of ATRA
(including pharmacological levels) activate both. These findings are in
keeping with studies that have reported that ATRA exerts
concentration-related biphasic effects on the proliferation of PC cell
lines when these cells are grown under serum free condi-
tions.11,35,57-63 Furthermore, we have shown that low levels of ATRA,
F IGURE 5 Antagonismof RARγ leads to caspase-independent apoptosis. (A) Serum-free adapted LNCaP cellswere treatedwithAGN194310or
AGN205728 as indicated, stainedwith propidium iodide and analyzed by flow cytometry. (B) Agarose gel electrophoresis analysis ofDNA from
AGN205728-treated LNCaP cells. (C) Serum-free adapted LNCaP cellswere treatedwith 10−6MAGN194310, AGN205728,or AGN196996 as indicated.
Time course of the appearance ofDNA-strand breakswas assessed by TUNEL assay (TACS-2 TdT Fluorescein in situ apoptosis detection kit). TUNEL-
positive cellswere counted for every 500 cells from five fields fromeach slide, and three different slideswere analyzed for each sample. Results are presented
as percentage of apoptotic cells (±SD). (D) Serum-free adapted LNCaP cellswere treatedwith 10−6MAGN205728 and the pan-caspase inhibitor Z-VAD-
FMKas indicated and assayed as described above. (E) Serum-free adapted LNCaP cellswere treatedwith 10−6MAGN205728, Z-VAD-FMK, or etoposide
(positive control) as indicated. Cleavage of caspase 3-,−8 or−9was assayed using the caspase-3 substrateDECD-AFC, the caspase-8 substrate IEHD-AFC
or the caspase-9 substrate LEHD-AFC, respectively. (F) Serum-free adapted LNCaP cellswere treatedwith docetaxel (10−10M), 5-fluorouracil (5 × 10−6M)
or etoposide (5 × 10−6M) alone or in combinationwithAGN205728 (10−7M) as indicated.Metabolic activity (intracellular ATP concentration)was
measured using theVialightHSHigh Sensitivity Cell Proliferation/Cytotoxicity assay. Statistical significance is represented as described in Section 2
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probably acting via RARγ, increase colony forming efficiency, promote
proliferation, and survival and oppose differentiation, suggesting that
stem-cells or early progenitors may be the target cell populations.
It is well-established that PC cell populations contain fractions
possessing mesenchymal stem cell-like properties and can be differen-
tiated into adipocytes,42,64 and we demonstrate that this can be
blocked by activation of RARγ. The differentiation cocktail used in this
study for the induction of adipogenesis in LNCaP cells included the
glucocorticoid agonist dexamethasone and the phosphodiesterase
inhibitor IBMX, the combination of which down-regulates expression
of RARγ in pre-adipocyte models.49 The down-regulation of RARγ
expression prior the onset of adipogenesis is an essential molecular
signature of several in vitro pre-adipocyte differentiation models48-50
while in vivo, an inverse correlation between RARγ expression and
adiposity has been demonstrated.48,65 Moreover, RARγ agonism
inhibits the expression of the pro-adipogenic nuclear receptor PPARγ
and thereby blocks the adipogenic signals emanating from this recep-
tor.46,51,66,67 Our observation that the addition of an RARγ agonist
prior to adipogenesis induction blocks PPARγ-stimulated adipogenesis
of LNCaP cells is consistent with these findings.
The deregulation of retinoic acid signaling in malignant cells also
has implications for the use of retinoids as chemotherapeutic agents. It
has long been known that pharmacological concentrations of ATRA
(> 10−7 M), acting via RARα, can drive malignant prostate cells into
growth arrest and apoptosis both in vitro and in vivo.68 However, high
dose retinoid treatment for PC, as well as most other solid tumors, has
had limited success in the clinic.18-20,69 Several issues contribute to this
failure, including acquisition of retinoid-resistance due to promoter
hypermethylation-mediated loss of RARβ expression in patients with
advanced PC.70-72 RARβ is known to play a role in driving growth arrest
in malignant prostate cells at physiological ATRA concentrations, so its
absence may provide a growth/survival advantage to the malignant cells
over their normal counterparts. Second, the altered biology of cancer
cells may negatively impact uptake, metabolism, storage of retinoids,
thus impeding the ability to achieve a high enough local concentrations
of ATRA to activate RARα. Indeed, pharmacodynamic studies have
shown that the plasma concentrations of ATRA (in the region of
2.2-0.4 μM) that have to be achieved before marginal clinical benefits
are observed are often associated with therapy-limiting toxicities.69
The pan-RAR agonistic activities of ATRA may well preferentially
activate RARγ over RARα in the tumor microenvironment53,55,73 and
our results indicate that antagonism RARγ may represent a better
therapeutic strategy. This notion is in agreement with our previous
findings that pan-RAR antagonists can induce caspase-independent
apoptosis more effectively that ATRA in PC cell lines.25 Our results
also suggest that RARγ antagonists may be effective in combination
with cytotoxic chemotherapy. We showed that a sub-maximally effec-
tive concentration of AGN205728 (10−7 M) significantly increased
the degree of cell death induced in serum free adapted-LNCaP cells
produced by sub-maximal concentrations of the taxane docetaxel, as
well as sub-optimal concentrations of the commonly used chemother-
apeutic agents 5-fluorouracil and etoposide. Docetaxel is used for the
treatment of castration-resistant PC but this is limited due to high
levels of toxicity (particularly neutropenia) and either innate or
acquired resistance in a significant percentage of patients. If the sensi-
tivity of PC towards taxanes and other therapeutic agents could be
increased, both the incidence of toxicity and the acquisition of resis-
tance may be reduced. Finally, while we performed experiments in
defined media in order to prevent ATRA and, potentially, androgens
or other factors found in fetal bovine serum from interfering with our
data, the androgen-deprived environment created mimics the clinical
scenario. Recent research indicates that androgen depravation
induces a neuroendocrine phenotype in LNCaP cells that is followed
by the acquisition of a “stem cell-like” state characterized by expres-
sion of markers including markers CD133, ALDH1A1, and ABCB1A.74
Many PC patients who are not cured with surgery or radiation and
subsequently undergo androgen deprivation therapy (ADT) develop
resistance to ADT and relapse with castration resistant prostate can-
cer (CRPC) that is associated with very poor outcome. Our data indi-
cate RARγ antagonism to be an effective approach in this context and
thus merits further investigation.
In conclusion, we have demonstrated that lower than normal con-
centrations of ATRA oppose differentiation, promote the survival and
proliferation of several PC cell lines by activating RARγ. We also
showed that RARγ antagonists alone can block proliferation of both
androgen-dependent and independent PC cell lines and eventual
induce caspase-independent apoptosis. Hence, RARγ antagonism
alone, or in combination with cytotoxic chemotherapy, may represent
a novel approach to the treatment of advanced prostate that targets
both androgen-dependent and androgen-independent PC cells.
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